Taysha Gene Therapies, Inc. Share Price
NASDAQ: TSHA | Mid CapTaysha Gene Therapies, Inc. Stock Performance
Open $6.41 | Prev. Close $6.33 | Circuit Range N/A |
Day Range $6.36 - $6.57 | Year Range $2.69 - $7.30 | Volume 1,32,892 |
Average Traded $6.45 |
Taysha Gene Therapies, Inc. Share Price Today
As of 10 August 2026, Taysha Gene Therapies, Inc.'s share price is $6.55. The stock opened at $6.41, compared to its previous close of $6.33. During today's trading session, Taysha Gene Therapies, Inc.'s share price traded between $6.36 and $6.57, with an average price of $6.46. Over the past 52 weeks, the stock has recorded a high of $7.30 and a low of $2.69. In terms of performance, Taysha Gene Therapies, Inc.'s share price has risen by 44.38% over the last six months and is up 124.49% on a year-on-year basis.
Taysha Gene Therapies, Inc. Share Price Chart
Taysha Gene Therapies, Inc. Stock Fundamentals & Key Indicators
Market Cap $2.10B | PE Ratio (TTM) -19.28 | Dividend Yield N/A |
EPS (TTM) $-0.34 | Revenue (TTM) $9.77M | Return On Equity (TTM) -44.14% |
Profit Margin -1115.27% | Debt to Equity 0.11 | Quarterly Earnings Growth YoY -28.24% |
Taysha Gene Therapies, Inc. Quarterly Profit & Loss
All figures in USD
Taysha Gene Therapies, Inc. Annual Profit & Loss
All figures in USD
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Taysha Gene Therapies, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $5.90 | $6.56 | +11.85% |
Jul 2026 | $6.71 | $5.87 | -13.94% |
Jun 2026 | $5.79 | $6.82 | +16.50% |
May 2026 | $6.33 | $5.85 | -8.16% |
Apr 2026 | $4.41 | $6.37 | +42.99% |
Mar 2026 | $4.47 | $4.46 | -1.87% |
Feb 2026 | $4.61 | $4.54 | +0.55% |
Jan 2026 | $5.48 | $4.51 | -17.76% |
Dec 2025 | $4.60 | $5.49 | +15.82% |
Nov 2025 | $4.33 | $4.74 | -4.44% |
Oct 2025 | $3.23 | $4.96 | +51.91% |
Sep 2025 | $2.92 | $3.27 | +11.82% |
TSHA Share Price FAQs
What is Taysha Gene Therapies, Inc. share price today?
What is the 52 week high and 52 week low of Taysha Gene Therapies, Inc. stock?
What is TSHA's market capitalisation today?
What is TSHA's net income for the last quarter?
What is the 5 year returns of TSHA?
What is the high & low stock price of TSHA today?
Can I buy TSHA shares in India?